Luteolin works synergistically with osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), to overcome acquired resistance in NSCLC cells by suppressing the hepatocyte growth factor (HGF)-MET-Akt signaling cascade, which is involved in MET amplification and hyperactivation (Huang G. et al., 2023). The gene discussed is MET; the disease is non-small cell lung carcinoma.